2019 Parkinson Study Group Symposium and Training

2019年帕金森研究组研讨会及培训

• 批准号: 9763271
• 负责人: MICHAEL A SCHWARZSCHILD
• 金额: $ 2.5万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2022-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9763271
• 关键词: Address; Advocate; Applications Grants; Ataxia; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Development; Disease; Dystonia; Education; Educational Activities; Educational workshop; Effectiveness; Ensure; Etiology; Faculty; Fostering; Foundational Skills; Foundations; Future; Genetic; Gilles de la Tourette syndrome; Goals; Grant; Human; Huntington Disease; Inherited; Investments; Knowledge; LRRK2 gene; Learning; Mentors; Methodology; Movement Disorders; Mutation; Neurobiology; Neurodegenerative Disorders; Neurology; Parkinson Disease; Participant; Pathogenesis; Patient Care; Patients; Peer Review; Pharmacology; Phenotype; Pilot Projects; Program Reviews; Research; Research Activity; Research Methodology; Research Personnel; Research Project Grants; Scientist; Series; Site; Study Section; Therapeutic; Training; Training and Education; Translational Research; Tremor; Writing; career; career development; clinical development; data mining; design; experience; genetic epidemiology; improved; insight; meetings; mobile computing; nervous system disorder; neuroimaging; novel; patient oriented; personalized medicine; posters; programs; research study; skills; statistics; symposium; therapeutic development

Abstract The proposed three-year conference project, centered on the annual clinical research symposium of the Parkinson Study Group (PSG) and associated annual meeting activities, will foster the education and training of early stage investigators to ensure that the highest quality translational and clinical research continues to be conducted toward improved therapy for Parkinson's and related neurological disease. This project goal will be achieved through two specific aims (SAs). In SA #1, the PSG will present its “32nd Annual Symposium on the Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders” in collaboration with the Huntington Study Group (HSG), Dystonia Study Group (DSG), Tourette Syndrome Study Group (TSSG), Cooperative Ataxia Group (CAG), and Tremor Research Group (TRG) on Saturday, April 6, 2019 in Phoenix, AZ, and the 33rd and 34th symposia annually thereafter. The peer-reviewed program includes both platform and poster presentations in a live format with audience participation. The symposia themes will authoritatively address major challenges and opportunities in pursuit of improved treatment for people with Parkinson's and other neurodegenerative diseases, with keynote talks conveying complementary neurobiological, clinical development and patient perspectives. The 2019 Symposium will cover the revolutionary impact of PD genetics, and GBA and LRRK2 mutations in particularly, on PD therapeutics development. SA #2 is designed to provide early-stage clinical investigators with movement disorders training a multi-faceted practical orientation to PD clinical research. The selected junior investigators will participate in several novel and interactive, educational research activities in addition to the symposium, including a) direct exchange with experienced patient advocates of the Parkinson's Foundation's PAIR (Parkinson's Advocates in Research) program to learn how patient input can benefit their research, and b) the PSG Mentoring Committee's junior investigator skills workshop with annually rotating themes spanning clinical research project development, grant proposal writing, and emerging research methodologies. Junior investigators completing participation in the project will be substantially better prepared and motivated to pursue careers and rigorous studies in clinical neurology.

抽象的 拟议的为期三年的会议项目，以年度临床研究研讨会为中心 帕金森研究小组 (PSG) 和相关的年会活动将促进教育和 培训早期研究人员，以确保最高质量的转化和临床研究 继续致力于改善帕金森病和相关神经系统疾病的治疗。 该项目目标将通过两个具体目标 (SA) 来实现。在 SA #1 中，PSG 将展示其 “第 32 届帕金森病的病因学、发病机制和治疗年度研讨会 其他运动障碍”与亨廷顿研究小组 (HSG) 合作，肌张力障碍研究 组 (DSG)、抽动秽语综合征研究组 (TSSG)、合作性共济失调组 (CAG) 和震颤组 研究小组 (TRG) 于 2019 年 4 月 6 日星期六在亚利桑那州凤凰城举行第 33 届和第 34 届研讨会 此后每年。同行评审的计划包括现场平台和海报展示 观众参与的形式。研讨会主题将权威地解决重大挑战 以及寻求改善帕金森病和其他疾病患者治疗的机会 神经退行性疾病，主题演讲传达了互补的神经生物学、临床知识 发展和患者的观点。 2019 年研讨会将涵盖 PD 的革命性影响 遗传学，特别是 GBA 和 LRRK2 突变对 PD 治疗开发的影响。 SA #2 是 旨在为早期临床研究人员提供运动障碍训练多方面的 PD临床研究的实践方向。入选的初级研究员将参加多项 除研讨会之外的新颖且互动的教育研究活动，包括 a) 直接 与帕金森病基金会 PAIR（帕金森病 研究倡导者) 计划，以了解患者的意见如何有益于他们的研究，以及 b) PSG 指导委员会的初级研究者技能研讨会每年轮换主题涵盖临床 研究项目开发、资助提案撰写和新兴研究方法。初级 完成参与该项目的研究人员将有更好的准备和动力 追求临床神经病学的职业和严格的研究。